Skip to main content
KYUNG NAM PHARM.CO.,LTD. logo

KYUNG NAM PHARM.CO.,LTD. — Investor Relations & Filings

Ticker · 053950 ISIN · KR7053950002 KO Manufacturing
Open in API
Filings indexed 428 across all filing types
Latest filing 2025-06-23 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 053950

About KYUNG NAM PHARM.CO.,LTD.

https://www.kyungnampharm.com:6519/eng/

Kyung Nam Pharm is a pharmaceutical company established in 1957 that specializes in over-the-counter (OTC) medicines and health functional foods. The company is widely known for its flagship brand, Lemona, which was the first powdered Vitamin C product in its domestic market and is now marketed as an inner-beauty product. The core product portfolio also includes PM, a topical treatment for athlete's foot, and Minol F Troche for sore throats. A key area of specialization is human placenta-based medicines; the company was a pioneer in developing and commercializing human placenta drink formulations. Kyung Nam Pharm focuses on developing accessible healthcare solutions based on its corporate philosophy of promoting human health.

Recent filings

Filing Released Lang Actions
전환가액의조정
Share Issue/Capital Change Classification · 1% confidence The document is an official regulatory filing regarding the adjustment of the conversion price for convertible bonds (전환가액의 조정). This type of disclosure relates to changes in the company's capital structure and financial instruments. Since it does not fit into specific categories like M&A, dividends, or director dealings, and is a standard regulatory disclosure filed with the exchange (KRX), it is classified as a Regulatory Filing.
2025-06-23 Korean
전환가액의조정
Share Issue/Capital Change Classification · 1% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) system regarding the adjustment of the conversion price for convertible bonds (CB). It details the specific changes to the conversion price, the number of convertible shares, and the underlying calculation methodology. This type of filing is a standard corporate disclosure related to capital structure and financing instruments, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like M&A or Dividend announcements.
2025-06-10 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and the purpose of holding (in this case, 'influencing management') by a major shareholder (Minish Technology Inc.) in a listed company (Kyungnam Pharm). This falls under the category of Major Shareholding Notification.
2025-05-21 Korean
분기보고서 (2025.03)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for Kyungnam Pharm Co., Ltd. for the first quarter of 2025 (제 28 기 1분기). It contains detailed financial data, business operations, and management information, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-05-15 Korean
전환가액의조정
Capital/Financing Update Classification · 1% confidence The document is a formal regulatory filing from a Korean company (Kyungnam Pharm) regarding the 'Adjustment of Conversion Price' (전환가액의 조정) for convertible bonds. This type of filing is a standard disclosure related to capital structure changes and financial instruments. In the provided taxonomy, 'Capital/Financing Update' (CAP) is the most appropriate category for adjustments to conversion prices of debt instruments, as it directly impacts the company's capital structure and potential equity dilution.
2025-05-12 Korean
전환가액의조정
Capital/Financing Update Classification · 1% confidence The document is an official regulatory filing from the Korea Exchange (KRX) regarding the adjustment of the conversion price for convertible bonds (CB). It details the specific changes in conversion price, the number of convertible shares, and the underlying reasons (market price decline). This falls under capital structure changes and financing updates, specifically categorized as a 'Capital/Financing Update' (CAP) in the provided schema.
2025-04-10 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.